Methylphenidate lacks genotoxic effects in mouse peripheral blood erythrocytes

Ana L. Zamora-Perez; Blanca P. Lazalde-Ramos; Martha G. Sosa-Macías; Belinda C. Gómez-Meda; Olivia Torres-Bugarín; Guillermo M. Zúñiga-González

doi:10.3109/01480545.2010.536770

Methylphenidate lacks genotoxic effects in mouse peripheral blood erythrocytes

Ana L. Zamora-Perez, Blanca P. Lazalde-Ramos, Martha G. Sosa-Macías, Belinda C. Gómez-Meda, Olivia Torres-Bugarín, Guillermo M. Zúñiga-González

Centro Interdisciplinario de Investigación para el Desarrollo Integral Regional (CIIDIR), Unidad Durango

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Methylphenidate (MPH; Ritalin^®; Novartis Pharmaceuticals, Inc., Basel, Switzerland) has been prescribed to treat attention deficit/hyperactivity disorder (ADHD) since its approval by the U.S. Food and Drug Administration over 50 years ago. Due to concerns that MPH might induce cytogenetic alterations in children, treatment with this drug has been a controversial issue. In the present study, we assessed the frequency of micronucleated erythrocytes (MNEs), micronucleated polychromatic erythrocytes (MNPCEs), and polychromatic erythrocytes (PCEs) in peripheral blood samples from mice treated with three different doses of MPH (30, 60, or 125 mg/kg). We found no evidence of increased MNEs or MNPCEs, nor did PCEs decline. These results add to the accumulating evidence that MPH does not induce genotoxic or cytotoxic damage.

Original language	English
Pages (from-to)	294-299
Number of pages	6
Journal	Drug and Chemical Toxicology
Volume	34
Issue number	3
DOIs	https://doi.org/10.3109/01480545.2010.536770
State	Published - Jul 2011

Keywords

Genotoxicity
Ritalin
micronuclei
mouse
peripheral blood erythrocytes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/01480545.2010.536770

Cite this

@article{885e6587bb274d38b85be22fd9256161,

title = "Methylphenidate lacks genotoxic effects in mouse peripheral blood erythrocytes",

abstract = "Methylphenidate (MPH; Ritalin{\textregistered}; Novartis Pharmaceuticals, Inc., Basel, Switzerland) has been prescribed to treat attention deficit/hyperactivity disorder (ADHD) since its approval by the U.S. Food and Drug Administration over 50 years ago. Due to concerns that MPH might induce cytogenetic alterations in children, treatment with this drug has been a controversial issue. In the present study, we assessed the frequency of micronucleated erythrocytes (MNEs), micronucleated polychromatic erythrocytes (MNPCEs), and polychromatic erythrocytes (PCEs) in peripheral blood samples from mice treated with three different doses of MPH (30, 60, or 125 mg/kg). We found no evidence of increased MNEs or MNPCEs, nor did PCEs decline. These results add to the accumulating evidence that MPH does not induce genotoxic or cytotoxic damage.",

keywords = "Genotoxicity, Ritalin, micronuclei, mouse, peripheral blood erythrocytes",

author = "Zamora-Perez, {Ana L.} and Lazalde-Ramos, {Blanca P.} and Sosa-Mac{\'i}as, {Martha G.} and G{\'o}mez-Meda, {Belinda C.} and Olivia Torres-Bugar{\'i}n and Z{\'u}{\~n}iga-Gonz{\'a}lez, {Guillermo M.}",

year = "2011",

month = jul,

doi = "10.3109/01480545.2010.536770",

language = "Ingl{\'e}s",

volume = "34",

pages = "294--299",

journal = "Drug and Chemical Toxicology",

issn = "0148-0545",

number = "3",

}

TY - JOUR

T1 - Methylphenidate lacks genotoxic effects in mouse peripheral blood erythrocytes

AU - Zamora-Perez, Ana L.

AU - Lazalde-Ramos, Blanca P.

AU - Sosa-Macías, Martha G.

AU - Gómez-Meda, Belinda C.

AU - Torres-Bugarín, Olivia

AU - Zúñiga-González, Guillermo M.

PY - 2011/7

Y1 - 2011/7

N2 - Methylphenidate (MPH; Ritalin®; Novartis Pharmaceuticals, Inc., Basel, Switzerland) has been prescribed to treat attention deficit/hyperactivity disorder (ADHD) since its approval by the U.S. Food and Drug Administration over 50 years ago. Due to concerns that MPH might induce cytogenetic alterations in children, treatment with this drug has been a controversial issue. In the present study, we assessed the frequency of micronucleated erythrocytes (MNEs), micronucleated polychromatic erythrocytes (MNPCEs), and polychromatic erythrocytes (PCEs) in peripheral blood samples from mice treated with three different doses of MPH (30, 60, or 125 mg/kg). We found no evidence of increased MNEs or MNPCEs, nor did PCEs decline. These results add to the accumulating evidence that MPH does not induce genotoxic or cytotoxic damage.

AB - Methylphenidate (MPH; Ritalin®; Novartis Pharmaceuticals, Inc., Basel, Switzerland) has been prescribed to treat attention deficit/hyperactivity disorder (ADHD) since its approval by the U.S. Food and Drug Administration over 50 years ago. Due to concerns that MPH might induce cytogenetic alterations in children, treatment with this drug has been a controversial issue. In the present study, we assessed the frequency of micronucleated erythrocytes (MNEs), micronucleated polychromatic erythrocytes (MNPCEs), and polychromatic erythrocytes (PCEs) in peripheral blood samples from mice treated with three different doses of MPH (30, 60, or 125 mg/kg). We found no evidence of increased MNEs or MNPCEs, nor did PCEs decline. These results add to the accumulating evidence that MPH does not induce genotoxic or cytotoxic damage.

KW - Genotoxicity

KW - Ritalin

KW - micronuclei

KW - mouse

KW - peripheral blood erythrocytes

UR - http://www.scopus.com/inward/record.url?scp=79958185815&partnerID=8YFLogxK

U2 - 10.3109/01480545.2010.536770

DO - 10.3109/01480545.2010.536770

M3 - Artículo

C2 - 21649484

AN - SCOPUS:79958185815

SN - 0148-0545

VL - 34

SP - 294

EP - 299

JO - Drug and Chemical Toxicology

JF - Drug and Chemical Toxicology

IS - 3

ER -

Methylphenidate lacks genotoxic effects in mouse peripheral blood erythrocytes

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this